Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis

Anticancer Res. 2018 Jan;38(1):205-210. doi: 10.21873/anticanres.12209.

Abstract

Background/aim: Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. The aim of this study was to analyze the combined anti-proliferative effect of cisplatin (CDDP) and osthole on a rhabdomyosarcoma cell line, and assess the pharmacology of drug-drug interaction between these drugs using isobolographic analysis.

Materials and methods: The anticancer actions of osthole in combination with CDDP were evaluated using the tetrazolium dye-based MTT cell proliferation assay.

Results: Osthole and CDDP applied together augmented their anti-cancer activities and yielded an additive type of pharmacologic interaction by means of isobolographic analysis.

Conclusion: Combined therapy using osthole and cisplatin could be suggested as a potential chemotherapy regimen against rhabdomyosarcoma.

Keywords: CDDP; Osthole; isobolography; rhabdomyosarcoma.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / pharmacology*
  • Coumarins / pharmacology*
  • Drug Synergism
  • Humans
  • Rhabdomyosarcoma / drug therapy*

Substances

  • Antineoplastic Agents
  • Coumarins
  • Cisplatin
  • osthol